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1 INTRODUCTION 
Influenza is worldwide one of the deadliest infectious 
diseases that can affect millions of people every year 
1
. 
Hemagglutinin (HA) and neuraminidase (NA) are 
essential for viral replication, infectivity, and the 
infective cycle of influenza. NA catalyzes removal of 
terminal sialic acid (SA) linked to glycoproteins and 
glycolipids. Scientific research suggested that NA is not 
only crucial in the release of virion progeny away from 
infected cells 
2
, but also important in the movement of 
the virus through mucus of respiratory tract and 
reducing the propensity of the virus particles to 
aggregate. Despite  the homology identity of NA in 
different strains is only about 30%, the catalytic site of 
NA in all influenza A and B virus is completely 
conserved 
3
. Therefore,  inhibitors that were designed to 
block the active site of NA could become an efficient 
treatment against the influenza. Rational design of 
neuraminidase inhibitors (NAIs) is now in the clinic and 
is effective for the treatment of influenza. Recently, 
research of structure-based NAIs is becoming an 
interesting field, leading to a breakthrough in the 
control of influenza 
4
.  The NA active site is highly 
polar, with ten Arg, Asp angd Glu residues and four 
hydrophobic residues 
5
. To facilitate the discussion of 
the inhibitor-binding modes, the active site of NA is 
divided into five regions: S1–S5 (Figure 1). These 
subsites are diagrammed and numbered in 
counterclockwise fashion using the crystal  structure of 
the substrate-based inhibitor dehydrodeoxy-N-
acetylneuraminic acid (DANA) bound to the active site 
6
. However, NAIs based on the structure of DANA were 
found to be rapidly excreted from physiological 
systems. Therefore, Jedrzejas et al. 
7
 developed a novel 
series of specific NAIs that were benzoic acid 
derivatives on the basis of NA-DANA complex. They 
found that the aromatic NAIs occupied the same site as 
DANA in the active site of NA. The coordinates of such 
inhibitors complexed with NA could be used as the 
starting model for further design of more potent benzoic 
acid NAIs. Over the past years, we have engaged in a 
project aimed at developing novel NAIs as antiviral 
agents. We have described the design and synthesis of a 
novel series of pyrrolidine derivatives as potent NAIs 
8
. 
As a further development of this project, we used 
benzene ring as a replacement of the dihydropyran ring 
of DANA (Figure 2). The benzene ring scaffold had 
advantages of non-chirality, chemical and metabolic 
stability, and increased lipophilicity compared  with the 
dihydropyran ring. In our previous work, we have 
described the synthesis and evaluation of a novel class 
of p-aminosalicylic acid (PAS) derivatives as potent 
influenza NAIs (Figure 2) 
9
. Molecular docking,  
quantitative structure–activity relationship (QSAR) 
studies and pharmacokinetics absorption, distribution, 
metabolism, and excretion (ADME) prediction for any 
given scaffold of interest are the most popular methods 
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of computer aided drug design 
10
. In our ongoing 
project, molecular docking, 3D-QSAR studies, and in 
silico ADME  prediction were carried out to better 
understand the structural basis for PAS NAIs. Herein, 
Surflex-Dock, comparative molecular field analysis 
(CoMFA), comparative molecular similarity indices 
analysis (CoMSIA) studies, and Volsurf analysis of 
pharmacokinetic properties of 40 PAS NAIs are 
described.  
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Figure 1: The chemical structure of compound
 
 
Table 1: Structure and activity of compounds 
S.No Compound R1 R2 R3 R4    pIC50 
1 A1 Me Et- H H 6.658 
2 A2 Me Et- NO2 NO2 5.939 
3 A3 Me Et- NH2 NH2 6.509 
4 A4 Me Et- =R4 N=C(NH2)2 7.444 
5 A5 H Et- =R4 N=C(NH2)2 7.495 
6 B1 Me i-pr H H 5.274 
7 B2 Me i-pr H NO2 6.244 
8 B3 Me i-pr H NH2 6.638 
9 B4 Me i-pr H N=C(NH2)2 6.921 
10 B5 H i-pr H N=C(NH2)2 7.309 
11 C1 Me n-pr H H 5.033 
12 C2 Me n-pr H NO2 5.447 
13 C3 Me n-pr H NH2 5.899 
14 C4 Me n-pr H N=C(NH2)2 5.996 
15 C5 H n-pr H N=C(NH2)2 6.143 
16 D1 Me s-Bu H H 5.527 
17 D2 Me s-Bu H NO2 5.799 
18 D3 Me s-Bu H NH2 6.022 
19 D4 Me s-Bu H N=C(NH2)2 6.131 
20 D5 H s-Bu H N=C(NH2)2 7.143 
21 E1 Me n-Bu H H 6.638 
22 E2 Me n-Bu H NO2 6.854 
23 E3 Me n-Bu H NH2 7.131 
24 E4 Me n-Bu H N=C(NH2)2 7.284 
25 E5 H n-Bu H N=C(NH2)2         7.409 
26 F1 Me isopentil H H 5.419 
27 F2 Me isopentil H NO2 5.529 
28 F3 Me isopentil H NH2 6.013 
29 F4 Me isopentil H N=C(NH2)2 6.745 
30 F5 H isopentil H N=C(NH2)2 7.387 
31 G1 Me 
CH3
 
H H 
6.308 
32 G2 Me 
CH3
 
H NO2 
6.48 
33 G3 Me 
CH3
 
H NH2 
6.74 
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34 G4 Me 
CH3
 
H N=C(NH2)2 
7.032 
35 G5 H 
CH3
 
H N=C(NH2)2 
7.252 
36 H1 Me cetyl H H 5.57 
37 H2 Me cetyl H NO2 5.727 
38 H3 Me cetyl H NH2 5.995 
39 H4 Me cetyl H N=C(NH2)2 6.059 
40 H5 H cetyl H N=C(NH2)2 6.159 
 
Table 2: Calculated Topological descriptors used in QSAR/QSPR Modeling 
Compd. 
no.    pIC50      MR      MV Parachor      IR  Surface T Density      X2      X3 
1 6.658 63.6 200.9 512.3 1.545 42.2 1.18 6.907 4.989 
2 5.939 76.7 224.6 623.2 1.598 59.3 1.457 9.76 7 
3 6.509 72.08 205.4 563.9 1.618 56.7 1.3 7.867 6.016 
4 7.444 85.26 235.6 655.1 1.643 59.7 1.49 10.714 7.088 
5 7.495 80.3 211.2 610.5 1.685 69.7 1.59 10.573 6.57 
6 5.274 66.48 210.4 530.9 1.544 40.7 1.117 7.266 5.1 
7 6.244 73.02 222.3 586.3 1.57 48.3 1.26 8.726 6.136 
8 6.638 70.71 212.7 556.7 1.579 46.8 1.176 7.796 5.579 
9 6.921 76.8 230 594.3 1.582 44.5 1.27 9.208 6.146 
10 7.309 71.84 205.6 549.7 1.615 51 1.35 9.066 5.627 
11 5.033 68.24 217.4 552.1 1.54 41.5 1.155 7.26 5.258 
12 5.447 74.78 229.2 607.5 1.566 49.3 1.292 8.721 6.295 
13 5.899 72.47 219.9 577.9 1.573 47.8 1.212 7.79 5.737 
14 5.996 78.38 237.4 621 1.574 46.8 1.29 9.202 6.304 
15 6.143 73.41 213 576.4 1.605 53.6 1.38 9.061 5.786 
16 5.527 72.83 234.3 589.2 1.534 40 1.132 7.867 5.731 
17 5.799 79.37 246.1 644.7 1.558 47 1.26 9.327 6.768 
18 6.022 77.06 236.5 615.1 1.565 45.6 1.184 8.397 6.211 
19 6.131 82.8 252.6 652.1 1.569 44.4 1.27 9.809 6.778 
20 7.143 77.84 228.2 607.5 1.597 50.2 1.35 9.668 6.259 
21 6.638 72.87 233.9 591.8 1.535 40.9 1.134 7.614 5.508 
22 6.854 79.42 245.7 647.3 1.559 48.1 1.262 9.074 6.545 
23 7.131 77.11 236.2 617.7 1.566 46.7 1.186 8.144 5.987 
24 7.284 82.99 253.5 659.6 1568 45.8 1.27 9.556 6.554 
25 7.409 78.02 229 615 1.596 51.9 1.34 9.414 6.036 
26 5.419 77.46 250.8 629 1.529 39.5 1.113 8.443 5.686 
27 5.529 84.01 262.6 684.5 1.552 46.1 1.234 9.903 6.723 
28 6.013 81.7 253 654 1.558 44.8 1.163 8.973 6.165 
29 6.745 87.41 268.7 690.7 1.564 43.6 1.25 10.385 6.732 
30 7.387 82.45 244.2 646.1 1.59 48.9 1.31 10.243 6.214 
31 6.308 75.39 229.1 599.9 1.571 46.9 1.21 8.504 6.44 
32 6.48 81.94 241 655.4 1.595 54.6 1.337 9.965 7.477 
33 6.74 79.63 231.4 625.7 1.604 53.4 1.262 9.034 6.92 
34 7.032 85.23 241.9 651 1.622 52.4 1.38 10.446 7.487 
35 7.252 80.27 217.5 606.4 1.659 60.4 1.47 10.305 6.968 
36 5.57 130 429.5 1086 1.517 40.8 1.046 12.21 8.758 
37 5.727 136.54 441.3 1141.5 1.53 44.7 1.12 13.67 9.795 
38 5.995 137.33 450.7 1134.9 1.521 40.1 1.026 12.74 9.237 
39 6.059 139.33 444.2 1136.1 2 42.7 1.14 14.152 9.804 
40 6.159 134.37 419.8 1091.5 1.553 45.6 1.17 14.011 9.286 
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In the present study, we have performed the quantitative 
structure activity relationship analysis by various 
regression methods. Regression methods are used to 
build a QSAR model in the form of a mathematical 
equation. This equation explains variation of one or 
more dependent variables (usually activity) in terms of 
independent variables. The QSAR model can be used to 
predict activities for new molecules, for screening a 
large set of molecules whose activities are not known. 
Multiple regression is the standard method for 
multivariate data analysis. Stepwise multiple regression 
(SMR) is an approach to select a subset of variables, 
when the numbers of independent variables 
(descriptors) are much more than the number of data 
points (molecules). SMR is a way of computing OLS 
regression in stages 
11-16
. It is also a procedure to 
examine the impact of each variable to the model step 
by step.  
2 MATERIAL AND METHODS  
Data set  
A data set of 40 molecules have been taken from the 
reputed published results 
17
. Anticancer activity was 
expressed as pIC50 values. [Table-1] It is essential to 
assess the predictive power of the models by using a 
test set of compounds. This was achieved by arbitrarily 
setting aside some compounds as a test set. The 
structures and anticancer activity data of compounds are 
listed in Table 1.  
Molecular structure generation  
All the molecular modeling and statistical analysis were 
performed using Vlife MDS software 
18-20
. The 
structures of the compounds were built using molecular 
sketching facilities provided in the modeling 
environment of Virus life. Energy minimization and 
batch optimization was carried out using Merck 
Molecular force field. All the molecules were initially 
optimized and then used for the calculation of 
descriptors and further QSAR study. 
 
Table 3: Correlation Matrix 
    pIC50      MR      MV PC      IR  ST Density      X2      X3 
   pIC50 1.0000         
     MR -0.1643 1.0000        
MV -0.2748 0.9860 1.0000       
Parachor -0.2223 0.9965 0.9946 1.0000      
IR 0.2125 -0.0115 -0.0089 -0.0140 1.0000     
ST 0.5497 -0.2243 -0.3696 -0.2733 -0.0562 1.0000    
DEN 0.6046 -0.3706 -0.5084 -0.4241 0.0222 0.9174 1.0000   
X2 0.0535 0.9227 0.8571 0.8970 0.0011 0.0634 -0.0194 1.0000  
X3 -0.0857 0.9469 0.9019 0.9347 -0.0118 -0.0152 -0.1611 0.9497 1.0000 
 
QSAR study  
All the 2D descriptors (thermodynamic, spatial, 
electronic and topological parameters) were calculated 
for QSAR analysis using Vlife MDS software. 
Thermodynamic parameters describe free energy 
change during drug receptor complex formation. Spatial 
parameters are the quantified steric features of drug 
molecules required for its complimentary fit with 
receptor. Electronic parameters describe weak non-
covalent bonding between drug molecules and receptor 
21-22
. Random Selection method and Sphere Exclusion 
Method were used for the selection of the training and 
test set. For variable selection Stepwise forward-
backward method was used. A suitable statistical 
method coupled with a variable selection method allows 
analyses of this data in order to establish a QSAR 
model with the subset of descriptors that are most 
statistically significant in determining the biological 
activity 
23-25
. The QSAR models were generated by 
Multiple Regression Analysis method.  
3 RESULTS AND DISCUSSION  
For QSAR analysis regression was performed using 
IC50 values as dependent variables and calculated 
parameters as independent variables. In any thorough 
investigation of the effects of molecular properties, it is 
essential to prove that the results are both statistically 
valid and make chemical sense. It would be appropriate 
to obtain insight into the physical meaning of the 
correlation obtained as an output of the regression 
analysis. The magnitude of a descriptor could be used 
as a guideline to improve the anticancer activity of 
molecules.
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Table 4: Results of regression analysis 
 
With reference to table 3, the selected descriptors are 
used for mono paramatric QSAR model no.1 
development which show the importance of 
physicochemical descriptor density which is directly 
proportional with the antiviral activity as 
Neuraminidase Inhibitors positively correlated. The 
monoparametric QSAR model No.1 is given below;  
pIC50=2.0860+ 3.4277DEN                                 Eq…1 
low statistical results indicates needs for the 
development of multiparametic and more QSAR 
models follow rule of thumb. The QSAR model no.2 
has significant importance in which MR has positive 
contribution with the antiviral activity while the Pc 
show inverse contribution with antiviral activity. The 
statistical descriptors are given in Table no.4 (Model 
No.2).  
pIC50= 5.1909+0.2805MR-3.3334E-02*PC          
                                                                              Eq…2 
The QSAR model no. 3 show their significant statistical 
importance with tri parametric model in which IR and 
MR are directly proportional with the antiviral activity 
while Pc are inversely proportional with the antiviral 
activity (QSAR model No.3). 
pIC50= 5.1771+ 5.254E-04*IR+ 0.2782MR-3.3057E-
02*PC Eq…3 
The above described all models are not statistically 
excellent indicates the deletion of outliers compound 
whose activity are not uniform and After deleting Comp 
No.,21,22 and 23 resulting the development of high 
statistically significant qsar model no.5 indicates that 
the MR play a major role in the antiviral activity. 
pIC50= 7.5527+ 5.6647E-04*IR+ 0.2477MR-
0.0676MV-4.0291E-02*ST-0.4135X3             Eq….4 
Among the generated QSAR models; three models were 
selected on the basis of various statistical parameters 
such as squared correlation co-efficient (r2) which is 
relative measure of quality of fit. Fischer’s value (F 
test) which represents F-ratio between the variance of 
calculated and observed activity.  
These models were generated in stepwise manner by 
forward-backward selection method starting with best 
single variable and adding further significant variable 
according to their contribution to the model. Various 
models of the data set were obtained which showed 
individual correlation of all calculated parameters with 
IC50 of anticancer activity. 
Eq. No. QSAR/QSPR Models N R
2
 R
2
adj MSE PRESS R
2
cv CV F-Ratio 
1 pIC50=2.0860+ 3.4277DEN 40 0.3656 0.3489 0.3081 12.84265 0.3043 0.870 21.898 
2 pIC50= 5.19097+0 .2805MR 
-3.3334E-02*PC 
40 0.5218 0.4959 0.2386 10.0181 0.4573 0.0765 20.186 
3 pIC50= 5.1771+ 5.2541E-04*IR 
 +0.2782MR-3.3057E-02*PC 
40 0.5575 0.5207 0.2269 493768.8 0.0000 0.0746 15.121 
4 pIC50= 6.1369+ 6.1647E-04*IR 
         + 0.1932MR 
          -4.9529E-02*MV 
          -0.5040X3 
40 0.5853 0.5379 0.2187 124978.1 0.0000 0.0733 12.349 
5 pIC50= 7.5527+ 5.664E-04*IR 
                       +0.2477MR 
                        -0.0676MV 
                        -4.0291E-02*ST 
                        -0.4135X3 
40 0.6063 0.5484 
 
 
 
0.2138 463744.1 0.0000 0.0724 10.471 
After deletion of compound no. 21,22 and 23 as outlier 
6 pIC50 = 7.5539+0.2784MR 
                        -7.6851E-02*MV 
                       + 6.0620E-04*IR 
                        -5.0431E-02*ST 
                        -0.3874X3 
37 0.7258 0.6815 0.1552 608814.8 0.0000 0.621 16.407 
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Table 5: Actual and predicted antiviral activity with residuals 
Row 
 
pIC50 
actual 
Predicted 
pIC50 
 
1 6.658 0.893 
2 5.939 -0.011 
3 6.509 -0.143 
4 7.444 0.01 
5 7.495 -0.13 
6 5.274 -0.596 
7 6.244 0.252 
8 6.638 0.26 
9 6.921 0.281 
10 7.309 0.301 
11 5.033 -0.687 
12 5.447 -0.392 
13 5.899 -0.304 
14 5.996 -0.338 
15 6.143 -0.54 
16 5.527 -0.065 
17 5.799 0.047 
18 6.022 -0.11 
19 6.131 -0.203 
20 7.143 0.406 
21 7.284 0 
22 7.409 0.683 
23 5.419 -0.237 
24 5.529 -0.309 
25 6.013 -0.202 
26 6.745 0.306 
27 7.387 0.513 
28 6.308 0.226 
29 6.48 0.279 
30 6.74 0.168 
31 7.032 -0.123 
32 7.252 -0.195 
33 5.57 0.272 
34 5.727 0.113 
35 5.995 0.436 
36 6.059 -0.206 
37 6.159 -0.654 
 
 
4 CONCLUSIONS  
In summary, from the derived QSAR model it can be 
concluded that antiviral  activity by the  Neuraminidase 
inhibitors is strongly influenced by the physicochemical 
descriptors  interactions and electro-topological nature of 
substituents. Pattern of substitution can be extracted from 
the developed model. The descriptors showed by QSAR 
study can be used further for study and designing of new 
compounds. Consequently this study may prove to be 
helpful in development and optimization of existing 
antiviral activity of this class of compounds. 
 
Figure 2: Graph plotted between predicted IC50 and actual 
IC50
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Figure 3: Graph plotted between k and Standardized beats of used descriptors in QSAR modeling 
 
Figure 4: Graph plotted between VIF and K of used descriptors in QSAR/QSPR modeling 
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